Annual Information Service
Biosimilar Index: Tracking the Biosimilar Development Landscape
|Published by||FirstWord||Product code||298599|
|Published||annual subscription||Content info|
Please contact us using the inquiry form for pricing information.
|Biosimilar Index: Tracking the Biosimilar Development Landscape|
|Published: annual subscription||Content info:||
FirstView's Biosimilar Index is a new, comprehensive drug intelligence service which provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type providing both on-going tracking of development and interpretation of the commercial and clinical significance.
The Biosimilars Index: Pipeline Database is checked daily. When a significant event happens, the database is updated, thereby ensuring you're up to date with current market dynamics. The database is provided as a dynamic MS Excel™ file with complete data and filter analysis tools included.
Available 24/7 through a secure password protected site, there are no limits on how frequently you can download the XLS file. Having access to the database enables you to see the whole biosimilar and NCB landscape across multiple classes and geographies
With Biosimilars Index: Pipeline Database at hand, you can effortlessly compare and contrast biosimilars in development by country, originator company, stage of development, condition and therapeutic area. The data is provided in MS Excel™ and comes with filters and search built in. The data can easily be exported to your own analytics package or data visualisation platform.
What's hot and what's not? The biosimilars sector is constantly evolving. Important research progress, commercial deals and product launches are regularly announced. The Biosimilar Index: Landscape Review strips away market rumour and speculation to tell you exactly what has happened and why it is important.
Published quarterly, the Review is based on the daily-updated research in the Biosimilar Index: Pipeline Database, enhanced by critical insights and understanding from biosimilars experts.
Whether you work in big pharma, a biosimilars development company, a clinical service organisation, a regulatory body or in commercial investment and finance, the Biosimilar Index provides a clear window on the world of biosimilar drugs and their developers.